Milk and Soured Milk (filmjölk) Intervention on Oxidative Stress and Inflammation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03821116

Recruitment Status : Recruiting

First Posted : January 29, 2019

Last Update Posted : March 24, 2020

See Contacts and Locations

Sponsor:

Collaborator:

Forte

Information provided by (Responsible Party):

Uppsala University

Study Description

Brief Summary:

This study evaluates a high intake of milk compared with a high intake of soured milk (Swedish filmjölk) on markers of oxidative stress and inflammation in a randomized crossover intervention study.

Condition or disease	Intervention/treatment	Phase
Oxidative Stress Inflammation	Other: Milk Other: Soured milk (filmjölk)	Not Applicable

Show detailed description

Detailed Description:

A diet rich in antioxidants reduces oxidative stress and inflammation and could potentially improve health and lower the rate of hip fracture. Milk and dairy are also promoted as part of a healthy diet since they contain 18 of 22 essential nutrients including calcium, phosphorous, and vitamin D and have been suggested to be associated with lower risk of cardiovascular disease, especially stroke, type 2 diabetes, and cancer. Meta-analyses of milk and dairy on fracture and mortality risk in cohort studies are, however, inconclusive and show significant heterogeneity between studies. Small intakes may have beneficial effects in comparison to null intake whereas higher intakes may have other effects and non-linear relationships are rarely examined. Frequently, different milk products are considered as one entity in cohort studies. The investigators recently showed that different milk products might have differential effects on disease. A high long-term milk intake was associated with an increased risk of mortality (total, cardiovascular, and cancer mortality) and hip fracture, especially among women, whereas a high long-term intake of fermented milk (soured milk and yogurt or cheese) was associated with a lower risk of mortality and fracture among women. Similar results have been presented for total mortality (Northern Sweden) and humeral fractures (South-Eastern Australia).

Intake of milk and fermented milk is of tradition high in Sweden. The prevalence of lactase persistence is high (around 95%). The range in milk intake from non- and low-consumers to high consumers makes Sweden an appropriate setting for epidemiological and interventional studies.

A common potential mechanism for intake of fruits, vegetables, and different dairy products on risk of disease is their influence on inflammation and oxidative stress. Chronic low-grade inflammation and age-related increase of oxidative stress are suggested pathogenic mechanisms of premature ageing and many diseases including cardiovascular disease, cancer, accelerated bone loss (leading to osteoporosis), and age-related reduction of muscle strength and mass (sarcopenia) with potential impacts on risk of falling and fracture. The lower risk of fractures with a high intake of fermented milk products observed may be due to potential probiotic, antioxidative, and anti-inflammatory effects and effects on gut microbiota. A high intake of milk was not only associated with risk of mortality and fractures but also with increased concentrations of inflammation and oxidative stress markers. An inverse association was seen for intake of soured milk and yogurt [Michaëlsson, 2014]. Fermented milk products with probiotics have been shown to reduce the levels of inflammation markers, other studies have been small to show conclusive effects and results may also be dependent on the probiotic strain. A head-to-head comparison of the effect of regular milk and soured milk (or yogurt) on markers of inflammation and oxidative stress in a randomized intervention study is warranted. The randomized crossover intervention study will be performed among both men and women.

The aim of the study is to examine the potentially different short-term effects of milk and sour milk on markers of oxidative stress and inflammation in a randomized cross-over trial. The research questions are:

In a randomized cross-over trial, what is the effect of a daily intake of at least 500 ml of Swedish milk compared with an intake of at least 500 ml Swedish soured milk (filmjölk) during 3 weeks on markers of oxidative stress and inflammation?
What are the effects of these milk products on a large number of proteins related with inflammation and ageing diseases, assessed with large-scale proteomic analysis?
What are the effects of these milk products on metabolites involved in inflammation and ageing diseases using large-scale metabolomics analysis?
What are the effects of these milk products on the gut microflora (microbiome)?

Changes in proteomics, metabolomics and the gut microbiome are other pre-specified outcome measures but since they are exploratory in nature, we do not specify them under outcomes since it is not possible to exactly specify these outcome measures. Exploratory analyses will include whether effects are different between men and women, dependent on body composition (assessed with whole body dual X-ray absorptiometry, DXA) or long-term dietary intake (assessed by fatty acid composition in subcutaneous fat). Participants will be allowed to consume more than 500 ml of milk/filmjölk during the intervention periods and, if possible, a potential dose-response effect will be evaluated.

Study Design

Layout table for study information

Study Type :	Interventional (Clinical Trial)
Estimated Enrollment :	70 participants
Allocation:	Randomized
Intervention Model:	Crossover Assignment
Masking:	None (Open Label)
Primary Purpose:	Basic Science
Official Title:	Milk and Soured Milk (filmjölk) Intervention on Oxidative Stress and Inflammation: A Randomized Crossover Intervention Study
Actual Study Start Date :	January 7, 2019
Estimated Primary Completion Date :	December 2020
Estimated Study Completion Date :	December 2020

Arms and Interventions

Arm	Intervention/treatment
Experimental: Milk At least 500 ml of Swedish milk daily for three weeks (crossover). Intervention and crossover preceded by 3 weeks with max 50 ml of milk or soured milk (filmjölk) daily. Fat content of milk and soured milk should be the same: 0.5%, 1.5% or 3%.	Other: Milk Swedish milk from cow.
Experimental: Soured milk (filmjölk) At least 500 ml of Swedish soured milk (filmjölk) daily for three weeks (crossover). Intervention and crossover preceded by 3 weeks with max 50 ml of milk or soured milk (filmjölk) daily. Fat content of milk and soured milk should be the same: 0.5%, 1.5% or 3%.	Other: Soured milk (filmjölk) Swedish soured milk (from cow milk).

Outcome Measures

Primary Outcome Measures :

Change in oxidative stress marker [ Time Frame: baseline and 3 weeks ]
urinary 8-iso-prostaglandin F2 alpha (8-iso-PGF2alpha)
Change in oxidative stress marker [ Time Frame: 6 weeks and 9 weeks ]
urinary 8-iso-prostaglandin F2 alpha (8-iso-PGF2alpha)

Secondary Outcome Measures :

Change in interleukin-6 (IL-6) [ Time Frame: baseline and 3 weeks ]
Inflammation marker, measured in serum
Change in interleukin-6 (IL-6) [ Time Frame: 6 weeks and 9 weeks ]
Inflammation marker, measured in serum
Change high sensitive C-reactive protein (hs-CRP) [ Time Frame: baseline and 3 weeks ]
Inflammation marker, measured in serum
Change high sensitive C-reactive protein (hs-CRP) [ Time Frame: 6 weeks and 9 weeks ]
Inflammation marker, measured in serum
Change in 15-keto-dihydro-prostaglandin F2 alpha (15-keto-dihydro-PGF2alpha) [ Time Frame: baseline and 3 weeks ]
Inflammation marker, a major metabolite of prostaglandin F2alpha, measured in urine
Change in 15-keto-dihydro-prostaglandin F2 alpha (15-keto-dihydro-PGF2alpha) [ Time Frame: 6 weeks and 9 weeks ]
Inflammation marker, a major metabolite of prostaglandin F2alpha, measured in urine

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	40 Years to 75 Years (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Tolerates both a low and a high intake of milk and soured milk
Agrees to comply with study protocol

Exclusion Criteria:

Inflammatory bowel disease
Major gastric tract operation
Pregnancy
Eating disorder

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03821116

Contacts

Layout table for location contacts

Contact: Liisa Byberg, PhD	+ 46 70 167 9400	liisa.byberg@surgsci.uu.se
Contact: Erika Olsson	+46 72 999 9344	milk@surgsci.uu.se

Locations

Layout table for location information

Sweden
Forskningsmottagning bentäthet, Kirurgiska vetenskaper, Uppsala Universitet	Recruiting
Uppsala, Sweden, 75185
Contact: Erika Olsson +46 72 999 9344 milk@surgsci.uu.se
Contact: Carina Fredriksson +46 18 611 7196 carina.fredriksson@regionuppsala.se
Principal Investigator: Liisa Byberg, PhD

Sponsors and Collaborators

Uppsala University

Forte

Investigators

Layout table for investigator information

Principal Investigator:	Liisa Byberg, PhD	Department of Surgical Sciences, Uppsala University

More Information

Publications:

Larsson SC, Crippa A, Orsini N, Wolk A, Michaëlsson K. Milk Consumption and Mortality from All Causes, Cardiovascular Disease, and Cancer: A Systematic Review and Meta-Analysis. Nutrients. 2015 Sep 11;7(9):7749-63. doi: 10.3390/nu7095363. Review.

Michaëlsson K, Wolk A, Langenskiöld S, Basu S, Warensjö Lemming E, Melhus H, Byberg L. Milk intake and risk of mortality and fractures in women and men: cohort studies. BMJ. 2014 Oct 28;349:g6015. doi: 10.1136/bmj.g6015.

Tognon G, Nilsson LM, Shungin D, Lissner L, Jansson JH, Renström F, Wennberg M, Winkvist A, Johansson I. Nonfermented milk and other dairy products: associations with all-cause mortality. Am J Clin Nutr. 2017 Jun;105(6):1502-1511. doi: 10.3945/ajcn.116.140798. Epub 2017 May 10.

Holloway KL, Bucki-Smith G, Morse AG, Brennan-Olsen SL, Kotowicz MA, Moloney DJ, Sanders KM, Korn S, Timney EN, Dobbins AG, Pasco JA. Humeral Fractures in South-Eastern Australia: Epidemiology and Risk Factors. Calcif Tissue Int. 2015 Nov;97(5):453-65. doi: 10.1007/s00223-015-0039-9. Epub 2015 Jul 14.

Layout table for additonal information

Responsible Party:	Uppsala University
ClinicalTrials.gov Identifier:	NCT03821116
Other Study ID Numbers:	MILK: EPN-Uppsala dnr 2018-328
First Posted:	January 29, 2019 Key Record Dates
Last Update Posted:	March 24, 2020
Last Verified:	March 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:	No

Layout table for additional information

Studies a U.S. FDA-regulated Drug Product:	No
Studies a U.S. FDA-regulated Device Product:	No

Additional relevant MeSH terms:

Layout table for MeSH terms

Inflammation Pathologic Processes

To Top